Analyzing...
Loading company...
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 407 full-time employees. The company went IPO on 2007-07-18. The firm is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The firm develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. The company has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. The company has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,879 Cr revenue.
COGS 1.3%, employees 6.3%.
“We need significant additional resources and are finalizing funding plan to extend cash flow through FY 'twenty eight, complete in first half of this calendar year.”
“Annual fixed cost savings of about $10,000,000 which is super significant relative to $50,000,000 ish annual spend.”
“we expect to have the maximum tolerated dose or the MTD identified by the end of the third quarter of twenty twenty six”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 116.0%▲ | 10.3% |
| ROCE | 112.0%▲ | 13.7% |
| Net Margin | 82.2%▲ | 7.6% |
| EBITDA Margin | 84.5%▲ | 15.4% |
| Debt To Equity | 0.42x▲ | 0.15x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | ₹1,879 Cr | ₹72 Cr -5.0% | ₹76 Cr |
| Other Income | ₹11 Cr +511.7% | ₹2 Cr -93.9% | ₹29 Cr |
| Total Income | ₹1,890 Cr | ₹74 Cr -30.0% | ₹105 Cr |
| COGS | ₹24 Cr +2.1% | ₹23 Cr -17.8% | ₹28 Cr |
| ₹325 Cr -22.0% | ₹416 Cr -15.4% | ₹492 Cr | |
| Profit Before Tax | ₹1,553 Cr ↑ Recovery | (₹343 Cr) +11.4% | (₹387 Cr) |
| Exceptional Items | (₹12 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| (₹0.19 Cr) +29.6% | (₹0.27 Cr) ↓ Decline | ₹0.38 Cr | |
| Net Profit | ₹1,553 Cr ↑ Recovery | (₹343 Cr) +11.5% | (₹387 Cr) |
| Profit (Owners) | ₹1,553 Cr ↑ Recovery | (₹343 Cr) +11.5% | (₹387 Cr) |
| Other Comprehensive Income | ₹3 Cr ↑ Recovery | (₹0.19 Cr) ↓ Decline | ₹0.20 Cr |
| EPS | ₹47.85 | (₹10.56) | (₹11.93) |
| Diluted Shares | ₹32 Cr | ₹32 Cr | ₹32 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Sun Pharma Advanced Research Company Limited has informed the Exchange about Receipt of requests for reclassification of shareholder category
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026 along with the Annual Report for FY 2025-26
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company.
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding allotment of 3,85,10,000 Warrants pursuant to Preferential Issue at its meeting held on May 19, 2026
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale of Priority Review Voucher for US $195 million".
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Significant increase in volume has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and...
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Addendum to the Valuation Report issued on January 14, 2026
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on February 09, 2026
Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the unaudited financial results for the period ended December 31, 2025.
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Board meeting held on February 09, 2026.
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "SPARC Announces Receipt of Priority Review Voucher associated with Sez...
No dividend history available for this company.